Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Harvard Business School
Colorcon
Dow
Medtronic

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 10,130,636

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,130,636
Title:High dosage strength tablets of rucaparib
Abstract: A tablet including high dosage of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[- 5,4,3-cd]indol-6-one camsylate salt has been disclosed.
Inventor(s): Etter; Jeffrey (Boulder, CO)
Assignee: Clovis Oncology, Inc. (Boulder, CO)
Application Number:15/920,643
Patent Claims: 1. A method of treating cancer in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a tablet comprising 45-90% w/w of an active pharmaceutical ingredient compound 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H- -azepino[5,4,3-cd]indol-6-one camsylate.

2. The method according to claim 1, wherein the active pharmaceutical ingredient is included in the range of 50-90%.

3. The method according to claim 1, wherein the active pharmaceutical ingredient is included in the range of 55-90%.

4. The method according to claim 1, wherein the active pharmaceutical ingredient is included in the range of 60-90%.

5. The method according to claim 1, wherein the active pharmaceutical ingredient is included in the range of 65-85%.

6. The method according to claim 1, wherein the active pharmaceutical ingredient is included in the range of 70-80%.

7. The method according to claim 1, wherein the tablet includes 200 mg or more of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-- azepino[5,4,3-cd]indol-6-one.

8. The method according to claim 1, wherein the tablet includes 250 mg or more of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-- azepino[5,4,3-cd]indol-6-one.

9. The method according to claim 1, wherein the tablet includes 300 mg or more of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-- azepino[5,4,3-cd]indol-6-one.

10. The method according to claim 1, wherein the mammal is a human being.

11. A method of treating cancer in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a dry granulated tablet comprising 45-90% w/w of an active pharmaceutical ingredient compound 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[- 5,4,3-cd]indol-6-one camsylate, wherein the tablet includes 200 mg or more of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepi- no[5,4,3-cd]indol-6-one.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Johnson and Johnson
AstraZeneca
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.